National Stroke Foundation


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved August 1999

Specific Treatments:


Therapeutic Areas

General Information

Raplon (rapacuronium bromide) has been approved as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures. Raplon was proven in studies to be an effective alternative to succinylcholine with a rapid onset and a short duration of action with the recommended dose.

Raplon is the first and only nondepolarizing neuromuscular blocking agent (NMBA) that combines both rapid onset with short duration for tracheal intubations and many short procedures including appendectomy, tonsillectomy, cystectomy, tubal ligation, and Cesarean section.